Qiagen NV
$ 45.60
0.51%
29 Dec - close price
- Market Cap 9,838,076,000 USD
- Current Price $ 45.60
- High / Low $ 46.02 / 45.44
- Stock P/E 24.52
- Book Value 16.83
- EPS 1.85
- Next Earning Report 2026-02-04
- Dividend Per Share $0.25
- Dividend Yield 0.55 %
- Next Dividend Date 2026-01-08
- ROA 0.08 %
- ROE 0.11 %
- 52 Week High 51.88
- 52 Week Low 37.43
About
Qiagen NV is a leading provider of sample-to-knowledge solutions, enabling the transformation of biological materials into critical insights for the life sciences, clinical diagnostics, and pharmaceutical industries. Based in Venlo, the Netherlands, the company utilizes cutting-edge genomic and proteomic technologies to empower researchers and healthcare professionals with comprehensive molecular data. With a strong focus on innovation and strategic partnerships, Qiagen is well-equipped to leverage the increasing demand for molecular testing and personalized healthcare, solidifying its position as a pivotal entity in the rapidly evolving healthcare landscape.
Analyst Target Price
$50.57
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-30 | 2024-04-28 | 2024-02-05 | 2023-10-30 | 2023-08-08 | 2023-05-02 | 2023-02-10 |
| Reported EPS | 0.61 | 0.6 | 0.55 | 0.61 | 0.59 | 0.57 | 0.37 | 0.57 | 0.53 | 0.54 | 0.54 | 0.56 |
| Estimated EPS | 0.59 | 0.6 | 0.51 | 0.62 | 0.56 | 0.53 | 0.35 | 0.57 | 0.51 | 0.53 | 0.49 | 0.49 |
| Surprise | 0.02 | 0 | 0.04 | -0.01 | 0.03 | 0.04 | 0.02 | 0 | 0.02 | 0.01 | 0.05 | 0.07 |
| Surprise Percentage | 3.3898% | 0% | 7.8431% | -1.6129% | 5.3571% | 7.5472% | 5.7143% | 0% | 3.9216% | 1.8868% | 10.2041% | 14.2857% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.59 |
| Currency | USD |
Previous Dividend Records
| Jul 2025 | Jan 1970 | Jan 1970 | |
|---|---|---|---|
| Payment Date | 2025-07-10 | None | None |
| Amount | $0.25 | $1.32 | $1.04 |
Next Dividend Records
| Dividend per share (year): | $0.25 |
| Dividend Yield | 0.55% |
| Next Dividend Date | 2026-01-08 |
| Ex-Dividend Date | 2025-07-02 |
Recent News: QGEN
2025-12-27 06:09:32
Qiagen (NYSE:QGEN) is scheduled to undergo a 19-20 reverse stock split before the market opens on January 8th, with shareholder share counts adjusting after the market close on January 7th. The company recently reported $0.61 EPS on $532.6 million in revenue, exceeding analyst estimates, and currently has a "Hold" consensus rating from analysts with an average target price of $49.61. Institutional investors hold approximately 70% of Qiagen's stock.
2025-12-25 01:09:32
Qiagen NV (QGEN.US) is set to perform a 19-for-20 reverse stock split, with shares trading on a split-adjusted basis from January 8th, 2026. On December 23rd, the stock closed at $45.61 with a market capitalization of $9.89 billion. A reverse stock split consolidates existing shares but does not directly impact a company's total value, often signaling distress.
2025-12-24 14:09:19
Voya Investment Management LLC significantly reduced its stake in Qiagen N.V. ($QGEN) during the third quarter, selling 141,669 shares, though institutional investors still hold a substantial portion of the company. Analyst sentiment remains mixed, with both "overweight" and "neutral" ratings issued recently, while Qiagen reported better-than-expected Q3 earnings and revenue. The stock currently trades in the mid-$40s with a market capitalization of approximately $10.14 billion.
2025-12-21 17:08:41
Wall Street Zen upgraded Qiagen (NYSE:QGEN) from a "hold" to a "buy" rating on Sunday, December 21, 2025. Despite this upgrade, the consensus among analysts remains a "hold" with an average price target of $49.61. Qiagen recently surpassed quarterly earnings and revenue estimates, showcasing modest year-over-year revenue growth.
2025-12-20 16:09:19
QIAGEN has announced a US$500 million synthetic share repurchase, combining a direct capital repayment with a reverse stock split, intended to reduce its share count by 5% by early January 2026. This action surpasses its prior commitment to return $1 billion to shareholders by 2028 and prompts a re-evaluation of the investment case, which now emphasizes the company's ability to expand recurring consumables revenue and manage future acquisitions given its improved shareholder return framework.
2025-12-19 17:09:36
QIAGEN N.V. announced it will complete its $500 million capital return to shareholders through a synthetic share repurchase on January 7, 2026. This plan combines a direct payment to shareholders with a reverse stock split, reducing outstanding shares by approximately 5%. The company has returned $1.15 billion to shareholders since early 2024, fulfilling its commitment ahead of schedule, and is considering further shareholder return measures.
